HQL News and Press, TeklaLife Sciences Investors From 10/31/22

Summary THW is still continuing with a steady monthly payout and generating close to double-digit yield, and it is relatively better protected from market risk. THW failed to grow during the past six months, as its major holdings failed to generate price growth. However, total ret...

Summary Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV, providing a better entry point. Tekla Life Sciences invests in a collection of biotechnology, pharmaceutical, diagnostics, and other healthcare-related companies. ...

Summary The market is going through a period of extraordinary uncertainty. It makes the task of investing and conserving capital hugely challenging. With index investing, there's no escape from a roller coaster ride. For most people, especially retirees, it's very difficult to tol...

Summary For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds are generally characterized by higher volatility and deeper drawdowns than the...

No portfolio or strategy can be perfect. We can only aim for it to be close to perfect. One such strategy, we believe, is what we call NPP (Near Perfect Portfolio) strategy. Be it a bull market, a bear market, or a stagnant market, the NPP strategy aims to provide decent growth, gener...

Tekla Life Sciences Investors is a closed-end fund focused on biotechnology and pharmaceutical stocks. The fund does not employ leverage and has an annualized 5-year total return of only 2.3% while its 10-year range annualized return sits at 9.8%. HQL significantly underperforms a...

Retirees and conservative investors need income, growth to exceed inflation, and most importantly, conservation of capital. Most investors find it difficult to tolerate large and deep drawdowns and want an escape from the roller coaster ride of the stock market. However, that is not p...

Tekla Life Sciences (NYSE:HQL) declares $0.35/share quarterly dividend, -10.3% decrease from prior dividend of $0.39. Forward yield 9.43% Payable June 30; for shareholders of record May 27; ex-div May 26. See HQL Dividend Scorecard, Yield Chart, & Dividend Growth. For further details se...

GRX’s total return has been negative, and yield has been quite average over the short term. GRX failed to record double digit average total return over the medium and long term. GRX has a quite high expense ratio and doesn’t have significant investments in any one st...

THW is a rare healthcare fund that performed well in April 2022 as well as in past 3 months and 3 years. THW is relatively better protected from market risk due to exposure in global equity markets. THW’s stock selection is impressive, and top investments generated high pos...